HALO (Halozyme Therapeutics) Other Long-Term Liabilities: $103 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HALO Halozyme Therapeutics Inc HALO
91 GF Score
Price $108.38
GF Value $98.91
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Halozyme Therapeutics Other Long-Term Liabilities?

Halozyme Therapeutics HALO -1.75% 91 Other Long-Term Liabilities is $103 Mil as of Jun. 2026. GuruFocus rates HALO with a GF Score™ of 91/100 and a GF Value™ of $98.91 (Fairly Valued). The stock has 5 warning signs investors should review.

Halozyme Therapeutics's other long-term liabilities for the quarter that ended in Jun. 2026 was $103 Mil.

Halozyme Therapeutics's quarterly other long-term liabilities declined from Dec. 2025 ($114 Mil) to Mar. 2026 ($106 Mil) and declined from Mar. 2026 ($106 Mil) to Jun. 2026 ($103 Mil).

Halozyme Therapeutics's annual other long-term liabilities increased from Dec. 2023 ($38 Mil) to Dec. 2024 ($55 Mil) and increased from Dec. 2024 ($55 Mil) to Dec. 2025 ($114 Mil).

Halozyme Therapeutics Other Long-Term Liabilities Related Terms

Halozyme Therapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Halozyme Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics Other Long-Term Liabilities Chart

Halozyme Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.54 48.16 37.72 54.76 113.86

Halozyme Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 77.77 71.80 113.86 106.45 102.68
HALO
91GF Score
Halozyme Therapeutics Inc HALO
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Halozyme Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $103 Mil mean?
Halozyme Therapeutics (HALO) has a Other Long-Term Liabilities of $103 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Halozyme Therapeutics and its competitors.
Is Halozyme Therapeutics' Other Long-Term Liabilities too high?
Halozyme Therapeutics' current Other Long-Term Liabilities is $103 Mil. Overall, Halozyme Therapeutics has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Other Long-Term Liabilities compare to ARWR and CORT?
Halozyme Therapeutics' Other Long-Term Liabilities of $103 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Other Long-Term Liabilities is $103 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Fairly Valued. The stock's GF Value™ is $98.91, compared to a current price of $108.38 — trading 9.6% above its estimated fair value. The current Other Long-Term Liabilities is $103 Mil. Halozyme Therapeutics' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Other Long-Term Liabilities is $103 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Halozyme Therapeutics (HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be overvalued. The current stock price of $108.38 is trading 9.6% above its estimated GF Value™ of $98.91. GuruFocus considers Halozyme Therapeutics to be Fairly Valued.

Key valuation signals for HALO:

  • Other Long-Term Liabilities: $103 Mil
  • GF Value™: $98.91 vs. price of $108.38 (9.6% above fair value)
  • GF Score™: 91/100 with 5 warning signs

No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Halozyme Therapeutics Business Description

Address 12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
91GF Score

Get the complete analysis for HALO

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$108.38
Price
$98.91
GF Value